Cyclin D1 expression in benign and differentiated malignant tumors of the thyroid gland: Diagnostic and biologic implications

Timothy P. Seybt, Preetha Ramalingam, Jie Huang, Stephen Warwick Looney, Michelle D. Reid

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Cyclin D1 expression was examined in benign and differentiated malignant thyroid tumors to determine diagnostic utility and correlation with tumor type, size, and nodal status; 29 follicular adenomas (FA), 23 follicular carcinomas (FCA) and 43 papillary thyroid carcinomas (PTC) (22 with and 21 without nodal metastases) were stained. PTCs included 27 classical (PTCC) and 16 follicular variants (PTCFV). A statistically significant association was found between tumor type and cyclin D1 staining, distribution, and intensity. There were fewer cyclin D1-positive FAs than PTCs (52% vs. 88% respectively; P<0.001) and stain distribution was greater in PTC than FA (P=0.032). More PTCs were positive than FCAs (88% vs. 61%, respectively; P=0.013). All significant comparisons remained significant after adjusting for tumor size. FA did not differ from FCA in staining/intensity. There were fewer cyclin D1-positive FAs than PTCC (52% vs. 89%, respectively; P=0.003) and PTCFV (52% vs. 88%, respectively; P=0.023). FCA also differed significantly from PTCC in staining (61% vs. 89%, respectively; P=0.044) and intensity (P=0.024). In terms of cyclin D1 intensity, FA had significantly less intense staining than PTCC (P=0.004). No significant associations were found between PTC nodal status and any cyclin D1 characteristic. In conclusion, cyclin D1 shows heterogeneity in distribution and intensity in benign and malignant thyroid tumors, which disqualifies it as a primary diagnostic marker in these tumors; however, it may be helpful in distinguishing FA from PTC, especially PTCFV. Its expression by thyroid tumors suggests a role in tumor development and may be an early event in thyroid neoplasia.

Original languageEnglish (US)
Pages (from-to)124-130
Number of pages7
JournalApplied Immunohistochemistry and Molecular Morphology
Volume20
Issue number2
DOIs
StatePublished - Mar 1 2012

Fingerprint

Cyclin D1
Factor IX
Thyroid Gland
Adenoma
Neoplasms
Staining and Labeling
Carcinoma
Tumor Biomarkers
Coloring Agents
Neoplasm Metastasis
Papillary Thyroid cancer

Keywords

  • cyclin D1
  • thyroid carcinoma
  • thyroid tumors

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Medical Laboratory Technology

Cite this

Cyclin D1 expression in benign and differentiated malignant tumors of the thyroid gland : Diagnostic and biologic implications. / Seybt, Timothy P.; Ramalingam, Preetha; Huang, Jie; Looney, Stephen Warwick; Reid, Michelle D.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 20, No. 2, 01.03.2012, p. 124-130.

Research output: Contribution to journalArticle

@article{f369f1b1df314eb78325331b6dfe2f19,
title = "Cyclin D1 expression in benign and differentiated malignant tumors of the thyroid gland: Diagnostic and biologic implications",
abstract = "Cyclin D1 expression was examined in benign and differentiated malignant thyroid tumors to determine diagnostic utility and correlation with tumor type, size, and nodal status; 29 follicular adenomas (FA), 23 follicular carcinomas (FCA) and 43 papillary thyroid carcinomas (PTC) (22 with and 21 without nodal metastases) were stained. PTCs included 27 classical (PTCC) and 16 follicular variants (PTCFV). A statistically significant association was found between tumor type and cyclin D1 staining, distribution, and intensity. There were fewer cyclin D1-positive FAs than PTCs (52{\%} vs. 88{\%} respectively; P<0.001) and stain distribution was greater in PTC than FA (P=0.032). More PTCs were positive than FCAs (88{\%} vs. 61{\%}, respectively; P=0.013). All significant comparisons remained significant after adjusting for tumor size. FA did not differ from FCA in staining/intensity. There were fewer cyclin D1-positive FAs than PTCC (52{\%} vs. 89{\%}, respectively; P=0.003) and PTCFV (52{\%} vs. 88{\%}, respectively; P=0.023). FCA also differed significantly from PTCC in staining (61{\%} vs. 89{\%}, respectively; P=0.044) and intensity (P=0.024). In terms of cyclin D1 intensity, FA had significantly less intense staining than PTCC (P=0.004). No significant associations were found between PTC nodal status and any cyclin D1 characteristic. In conclusion, cyclin D1 shows heterogeneity in distribution and intensity in benign and malignant thyroid tumors, which disqualifies it as a primary diagnostic marker in these tumors; however, it may be helpful in distinguishing FA from PTC, especially PTCFV. Its expression by thyroid tumors suggests a role in tumor development and may be an early event in thyroid neoplasia.",
keywords = "cyclin D1, thyroid carcinoma, thyroid tumors",
author = "Seybt, {Timothy P.} and Preetha Ramalingam and Jie Huang and Looney, {Stephen Warwick} and Reid, {Michelle D.}",
year = "2012",
month = "3",
day = "1",
doi = "10.1097/PAI.0b013e31822d4783",
language = "English (US)",
volume = "20",
pages = "124--130",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Cyclin D1 expression in benign and differentiated malignant tumors of the thyroid gland

T2 - Diagnostic and biologic implications

AU - Seybt, Timothy P.

AU - Ramalingam, Preetha

AU - Huang, Jie

AU - Looney, Stephen Warwick

AU - Reid, Michelle D.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Cyclin D1 expression was examined in benign and differentiated malignant thyroid tumors to determine diagnostic utility and correlation with tumor type, size, and nodal status; 29 follicular adenomas (FA), 23 follicular carcinomas (FCA) and 43 papillary thyroid carcinomas (PTC) (22 with and 21 without nodal metastases) were stained. PTCs included 27 classical (PTCC) and 16 follicular variants (PTCFV). A statistically significant association was found between tumor type and cyclin D1 staining, distribution, and intensity. There were fewer cyclin D1-positive FAs than PTCs (52% vs. 88% respectively; P<0.001) and stain distribution was greater in PTC than FA (P=0.032). More PTCs were positive than FCAs (88% vs. 61%, respectively; P=0.013). All significant comparisons remained significant after adjusting for tumor size. FA did not differ from FCA in staining/intensity. There were fewer cyclin D1-positive FAs than PTCC (52% vs. 89%, respectively; P=0.003) and PTCFV (52% vs. 88%, respectively; P=0.023). FCA also differed significantly from PTCC in staining (61% vs. 89%, respectively; P=0.044) and intensity (P=0.024). In terms of cyclin D1 intensity, FA had significantly less intense staining than PTCC (P=0.004). No significant associations were found between PTC nodal status and any cyclin D1 characteristic. In conclusion, cyclin D1 shows heterogeneity in distribution and intensity in benign and malignant thyroid tumors, which disqualifies it as a primary diagnostic marker in these tumors; however, it may be helpful in distinguishing FA from PTC, especially PTCFV. Its expression by thyroid tumors suggests a role in tumor development and may be an early event in thyroid neoplasia.

AB - Cyclin D1 expression was examined in benign and differentiated malignant thyroid tumors to determine diagnostic utility and correlation with tumor type, size, and nodal status; 29 follicular adenomas (FA), 23 follicular carcinomas (FCA) and 43 papillary thyroid carcinomas (PTC) (22 with and 21 without nodal metastases) were stained. PTCs included 27 classical (PTCC) and 16 follicular variants (PTCFV). A statistically significant association was found between tumor type and cyclin D1 staining, distribution, and intensity. There were fewer cyclin D1-positive FAs than PTCs (52% vs. 88% respectively; P<0.001) and stain distribution was greater in PTC than FA (P=0.032). More PTCs were positive than FCAs (88% vs. 61%, respectively; P=0.013). All significant comparisons remained significant after adjusting for tumor size. FA did not differ from FCA in staining/intensity. There were fewer cyclin D1-positive FAs than PTCC (52% vs. 89%, respectively; P=0.003) and PTCFV (52% vs. 88%, respectively; P=0.023). FCA also differed significantly from PTCC in staining (61% vs. 89%, respectively; P=0.044) and intensity (P=0.024). In terms of cyclin D1 intensity, FA had significantly less intense staining than PTCC (P=0.004). No significant associations were found between PTC nodal status and any cyclin D1 characteristic. In conclusion, cyclin D1 shows heterogeneity in distribution and intensity in benign and malignant thyroid tumors, which disqualifies it as a primary diagnostic marker in these tumors; however, it may be helpful in distinguishing FA from PTC, especially PTCFV. Its expression by thyroid tumors suggests a role in tumor development and may be an early event in thyroid neoplasia.

KW - cyclin D1

KW - thyroid carcinoma

KW - thyroid tumors

UR - http://www.scopus.com/inward/record.url?scp=84857911022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857911022&partnerID=8YFLogxK

U2 - 10.1097/PAI.0b013e31822d4783

DO - 10.1097/PAI.0b013e31822d4783

M3 - Article

C2 - 22553812

AN - SCOPUS:84857911022

VL - 20

SP - 124

EP - 130

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 2

ER -